Compare ACADIA Pharmaceuticals Inc. (ACAD) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs NRG Energy Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.56 (market cap $5.07B), while NRG Energy Inc trades at $122.3 (market cap $24.83B). The key difference: NRG Energy Inc is far larger — about 4.9× ACADIA Pharmaceuticals Inc.'s market cap, and NRG Energy Inc pays a 1.61% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | NRG | |
|---|---|---|
Market Cap | $5.07B | $24.83B |
Sector | Health | Utilities |
52-Week High | $29.41 | $184.03 |
52-Week Low | $20.06 | $117.04 |
Enterprise Value | $4.19B | $48.79B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
NRG Energy trades at $118.91, down 0.66% today, with a bearish technical signal. Recent Q2 2026 earnings missed estimates, but revenue grew 11% year-over-year. The company is expanding with a 1.2 GW Texas data-center power project, targeting long-term EBITDA growth. Valuation metrics show a P/E of 30.76 and P/S of 0.72, with strong ROE at 26.77% but modest net income margin of 2.56%. Cash flow trends are volatile, with 2025 net cash flow at $3.83B but a projected decline in 2026.
Outlook: Growth driven by data-center demand and strategic acquisitions offers upside, but high debt and earnings misses pose risks. Analyst consensus is bullish with a $207.83 price target, though technical weakness and rising interest costs require caution. Key opportunities include hyperscaler partnerships, while risks involve leverage and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
